Cyber Surgery has launched Alaya, a surgical robotic assistant for spine procedures, in Europe.

Alaya was designed, developed, and manufactured in Spain’s Basque Country. According to the company’s it’s the first robotic spine assistant with patented Kinematic Navigation Technology to enter the market.

Kinematic Navigation Technology aims to overcome the limitations of conventional optical navigation technologies. Optical systems depend on cameras, calibration, and line of sight. Kinematic Navigation Technology provides continuous, stable tracking in any surgical setting and reduces radiation exposure for patients and surgeons.

It also features a streamlined workflow with quicker setup and uninterrupted navigation. A reduced operating room footprint also allows for easier integration into hospitals.

Cyber Surgery said its robotic spine assistant can help reduce bleeding and/or infection risks, shorten patient recovery times, and empower surgeons with more precision and efficiency.

The company was founded in San Sebastián in 2017 and become a pioneer in surgical robotics. It began as a research spinoff of Egile and grown into a company that provides innovation, clinical excellence, and dedication to advancing healthcare.

“We would like to express our gratitude to our partners Egile, IMQ, Geroa, the Basque Government Venture Capital Fund, and the business angels who believed in this project from the very beginning,” Cyber Surgery said in a press release. “We would also like to thank the technology centers Ceit, Vicomtech, Tecnalia, and Tekniker for their decisive contribution to the development of our technology. We thank the Osakidetza hospitals—Hospital Universitario de Donostia, Hospital Universitario de Cruces, and Hospital Universitario Araba— together with BIOEF and the research institutes IIS BioGipuzkoa, BioBizkaia, and BioAraba, for their participation in clinical trials and validations.”

“Thanks also go to the institutions that have supported us along the way, including the Basque Government and SPRI, the Gipuzkoa Provincial Council, Fomento San Sebastián, the Ministry of Science and Innovation, and BIC Gipuzkoa,” the company went on. “We extend our deepest appreciation to the clinicians leading the clinical trials, Nicolás Samprón (Hospital Universitario de Donostia) and Iñigo Pomposo (Hospital Universitario de Cruces). We also thank the members of our Medical Advisory Board members —Jesús Lafuente, Florian Ringel, Marcel Ivanov, and Roger Härtl— for sharing their knowledge and international perspective.”